ArticleKorean journal of radiology2020
Clinical Study on Safety and Efficacy of Microwave Ablation for Primary Hyperparathyroidism.
Article in Korean journal of radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Percutaneous microwave ablation of hyperfunctioning parathyroid lesions under multiparametric ultrasound guidance for primary hyperparathyroidism: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Radiofrequency ablation for patients with primary hyperparathyroidism: a multicenter non-randomized open-label single-arm prospective clinical trial.European radiology · 2026Trial
- Long-term outcomes and prognostic factors following microwave ablation vs surgical resection for primary hyperparathyroidism.European radiology · 2026Article
- Efficacy and safety of ultrasound-guided microwave ablation for primary hyperparathyroidism: a dual-centre study.Scientific reports · 2026Article
- Interventional Radiology in the Management of Parathyroid Disorders: Current Diagnostic and Therapeutic Approaches.Journal of clinical medicine · 2026Review
- Short-term biochemical outcomes after microwave ablation versus parathyroidectomy for primary hyperparathyroidism: an IPTW analysis.Frontiers in endocrinology · 2026Article
- Assessment of renal stiffness in primary hyperparathyroidism using shear-wave elastography and changes after microwave ablation.Ultrasonography (Seoul, Korea) · 2025Article
- Evaluation of the efficacy of radiofrequency ablation therapy in cases with parathyroid adenoma.Turkish journal of medical sciences · 2025Article
- Case report: Microwave ablation is a safe and effective method for primary hyperparathyroidism in pregnancy.Frontiers in medicine · 2024Article
- Effectiveness and safety of the radiofrequency ablation of single hyperfunctioning parathyroid lesions suggestive of adenomas in primary hyperparathyroidism.Journal of endocrinological investigation · 2023Article
- Efficacy and safety of radiofrequency ablation for primary and secondary hyperparathyroidism: a retrospective study.Scientific reports · 2023Article
- Ultrasound-guided microwave ablation in the treatment of recurrent primary hyperparathyroidism in a patient with MEN1: a case report.Frontiers in endocrinology · 2023Article
- Predicting ultrasound-guided thermal ablation benefit in primary hyperparathyroidism.European radiology · 2022Article
- Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Primary Hyperparathyroidism: A Prospective Study.Korean journal of radiology · 2022Article
- Evaluation of efficacy of ultrasound-guided microwave ablation in primary hyperparathyroidism.Journal of clinical ultrasound : JCU · 2022Article
- A study on the causes of operative failures after microwave ablation for primary hyperparathyroidism.European radiology · 2021Article
- [Normocalcemic with elevated post-operative parathormone in primary hyperpara-thyroidism: 9 case reports and literature review].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2021Review
- Primary Hyperparathyroidism in Pregnancy: Insights From a Case of a 28-Year-Old Woman With Miscarriages and Hyperemesis Gravidarum.Annals of laboratory medicine · 2021Article
- Bone Turnover Markers in Response to Ultrasound-Guided Microwave Ablation for Primary Hyperparathyroidism.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the safety, feasibility, and efficacy of microwave ablation (MWA) for the treatment of primary hyperparathyroidism (PHPT). MATERIALS AND
methodsThis study enrolled 67 PHPT patients (22 men, 45 women; mean age, 56.0 ± 16.3 years; range, 18-83 years) from January 2015 to December 2018. The laboratory data, including the serum intact parathyroid hormone (iPTH), calcium, phosphorus, and alkaline phosphatase (ALP) levels, were evaluated before MWA and again 2 hours, 1 day, 7 days, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months after.
resultsComplete ablation was achieved with all 72 hyperplastic parathyroid glands found on the 67 patients enrolled, 64 of whom were treated in one session and 3 were treated over two sessions. The technical success rate was 100%. The median follow-up time was 13.6 months (range, 10.0-31.1 months). The clinical success rate was 89.4%. The volume reduction rate was 79.4% at 6 months. Compared to pre-MWA, the serum iPTH, calcium, phosphorus, and ALP levels had significantly improved 6 months post-MWA (iPTH, 157.3 pg/mL vs. 39.2 pg/mL; calcium, 2.75 ± 0.25 mmol/L vs. 2.34 ± 0.15 mmol/L; phosphorus, 0.86 ± 0.20 mmol/L vs. 1.12 ± 0.22 mmol/L; ALP, 79 U/L vs. 54 U/L, respectively; all,
conclusionMWA is safe, feasible, and effective for the treatment of PHPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.